Rohan Halder (@Rohanhematdoc) header
Rohan Halder (@Rohanhematdoc) profile picture

Clinical hematologist; Transplant physician

New Delhi, India
Joined January 2020
Photo by Rohan Halder (@Rohanhematdoc)Photo by Rohan Halder (@Rohanhematdoc)Photo by Rohan Halder (@Rohanhematdoc)Photo by Rohan Halder (@Rohanhematdoc)
Rohan Halder retweeted
NPM1 mutations are considered good risk in AML, but variant allele frequency (VAF) matters! A VAF > 31.44% suggests that the mutation has a wide clonal penetrance, making the AML more chemo-sensitive with greater chance of cure with intensive treatment However, if VAF < 31.44%, then the mutation is not in the predominant clone, and usually some other mutation or mutations are at play that will mediate future relapse ashpublications.org/blood/ar…
1
27
93
3,778
Does myeloma maintenance need to continue indefinitely? I spoke with @AJMC_Journal's Maggie Shaw about ENDURANCE, lenalidomide maintenance and balancing disease control with toxicity, quality of life & MRD-guided care. It's not just about living longer, but living better. ajmc.com/view/prerna-mewawal… #mmsm
4
11
434
Rohan Halder retweeted
Yes, the #Hennur - Bagalur road is in shambles. The GBA / BWSSB / Panchayat all need to immediately take this up. People are just suffering @GBA_office @BECCUPDATES @BNCCofficial Thx - @naveenmzs
12
15
2
65
2,544
Great work indeed. Thanks to the @RGCI_RC and @narendra_ag1 sir led PICC program, we have trained nursing staff doing fabulous job of PICC insertion in remote places like Rajkot. Highly indebted to them. Dr Narendra Agrawal sir has silently trained thousands of nursing and other doctors over years, who have visited from India and other countries, and has contributed to the cancer care.
In hemato-oncology, finding the right vein is clinical skill, and making vascular access safer is science! 🩸 Pleased to have contributed to this study of a nurse-led PICC program involving 1,026 patients. Read: link.springer.com/article/10… #Hematology #HematoOncology
1
1
11
562
It’s a government and law enforcement responsibility what’s get into the market . Not the hospital or doctors. Do you think it’s hospital or doctor job to test individual drugs before administering each patient. ?? Why do you have an FDA and government for ? You don’t blame a car company for an accident driving their car on a bad road. We have to get the responsibility part straight otherwise you will never get your answers. Extremely sorry for your loss. We have always asked for cheaper drugs in India. And never for high quality drugs. We get what we ask for.
unavailable
3
10
505
31
63
5
355
881,142
Rohan Halder retweeted
Details of the appropriately named ENDURANCE trial below. First randomization showed KRd (expensive) is not better than VRd Second randomization showed indefinite maintenance (very expensive) not better than limited duration maintenance. The type of trial that’s possible jnkt through the NCTN groups @theNCI in the US.
Just out!! In @NEJM - Our randomized trial in myeloma (ENDURANCE trial) shows limited duration of lenalidomide maintenance is just as good as indefinite therapy, with less side effects!!! @eaonc @theNCI Implications are HUGE. This is a drug we spends billions on each year: -Less side effects -Less second cancers -Similar overall survival -Less cost @myelomaMD @Myeloma_Doc @SagarLonialMD National NCI funded trial led by @eaonc and joined by @ALLIANCE_org & @SWOG nejm.org/doi/full/10.1056/NE…
1
8
1
22
5,603
Rohan Halder retweeted
Celebrating our @NEJM paper that showed that 2 years of lenalidomide maintenance is sufficient in myeloma. A 15 year journey. The results of this trial will in my opinion save over a billion dollars a year for Medicare. @myelomaMD as the PI worked tirelessly and I’m so fortunate to have him as a dear friend and colleague. @eaonc @theNCI
30
55
6
589
23,650
Rohan Halder retweeted
Just out!! In @NEJM - Our randomized trial in myeloma (ENDURANCE trial) shows limited duration of lenalidomide maintenance is just as good as indefinite therapy, with less side effects!!! @eaonc @theNCI Implications are HUGE. This is a drug we spends billions on each year: -Less side effects -Less second cancers -Similar overall survival -Less cost @myelomaMD @Myeloma_Doc @SagarLonialMD National NCI funded trial led by @eaonc and joined by @ALLIANCE_org & @SWOG nejm.org/doi/full/10.1056/NE…
37
200
34
579
140,482
The selection of CML Papers for June is now available. From the many CML papers published in June, Professor Timothy Hughes has selected interesting clinical, scientific, pediatric and LMIC publications. 📖 Explore the full list of papers on our website: buff.ly/VVned53
1
2
2
204
With Tal-Dara published and concerns about ataxia/ balance disorders lets take a deep dive on GPRC5D ataxia syndrome -> The first report of a cerebellar syndrome from GPRC5D came from MCARH019 reported by Mailankody et al -2/17 (12%) Grd 3 cerebellar syndrome -6.5 and 8.4 mo's after infusion -was a DLT at 450*10^6
4
14
2
38
8,619
Now that we have commercial access to BCMA Bispecifics in Myeloma, how important is it to have an assay for sBCMA? How would one use it in clinical practice?
42
#ASCO26 #mmsm Oral sessions myeloma PERSEUS outcomes based on new definition of high risk disease Sustained MRD negativity seem to make the outcome of high risk similar to standard risk, imp to be sustained over multiple years
3
1
12
731
India faces a major healthcare burden of Transfusion Dependent Thalassemia. Transplant is a curative treatment available for patients who have a Matched sibling donor. An important question that arises is does transplant make a difference in long term quality of life
2
1
3
83
A thank you to all the Co authors in the study and of course the patients. @dbhurani @Reema_Shayra #Thalassemia #QoL #HSCT
1
32
We did a cross-sectional comparative study of 100 age- and sex-matched children under 18 years old: Transplant (Tx) Group: 41 patients at least 2 years post-HSCT (median: 13 years). Non-Transplant (NTx) Group: 59 patients receiving conventional treatment (median: 10 year
2
1
92
Used The PedsQL 4.0 Generic Core Scales to assess QOL. Significant Overall Improvement: The transplant (Tx) group scored significantly higher across all domains of health-related quality of life compared to the non-transplant (NTx) group (p < 0.05). This includes improvements
28